November 24 -- Hubei Guangji Pharmaceutical (000952.SZ), a producer of pharmaceuticals, feed additives and food additives, will invest 20 million yuan to set up a wholly-controlled subsidiary in the Wuhan National Bio Industrial Park for the research of microbiology and high-tech pharmaceuticals, reports yicai.com, citing a company filing.

Once it is operational, the subsidiary will become the company's research platform in Wuhan, with a focus on pharmaceuticals, Chinese medicines, health care products, and additives.